Nifty Healthcare Index News and Updates

Name: Latest research reports of Abbott India Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Abbott India Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Keep track of all breaking news on Nifty Healthcare Index from all sources in a single place.

Load latest

Laurus Labs Ltd.

11 Apr 2025

628.05

0.18%

Laurus Labs surges 8%, stock records sharpest intraday gain since Jan 30

Business Standard

The pipeline is expected to be robust, and the company expects to do well in the human health and animal health CDMO divisions in Q4FY25E and in FY26E, according to analysts.

Laurus Labs Ltd. has gained 45.58% in the last 1 Year

Biocon Ltd.

11 Apr 2025

331.30

0.65%

Biocon shares jump 5.5% as USFDA clears biosimilar Cancer drug JOBEVNE

livemint

Biocon's share price rose 5.5% after USFDA approved JOBEVNE, a biosimilar cancer drug. This marks the company's seventh USFDA-approved biosimilar and enhances its oncology portfolio, increasing investor confidence and market optimism.

Number of FII/FPI investors increased from 297 to 305 in Mar 2025 qtr.

Biocon subsidiary gets USFDA nod for Everolimus tablets; share zooms 6%

Business Standard | 11 Apr 2025 1 more

Cipla Ltd.

11 Apr 2025

1515.20

1.26%

Cipla gets USFDA nod to market generic version of cancer drug Abraxane

Business Standard

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug. The company has received the final approval from the US Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) submitted for paclitaxel protein-bound particles for injectable suspension (albumin-bound), 100 mg/vial, single-dose vial, Cipla said in a regulatory filing. Cipla's protein-bound paclitaxel is a generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for injectable suspension 100 mg/vial. Protein-bound paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas. The product is expected to be launched in the first half of the current fiscal year in the US, the Mumbai-based drugmaker said. Shares of the company were trading 2.73 per cent up at Rs 1,454.90 apiece on the BSE.

Number of FII/FPI investors decreased from 1132 to 1077 in Dec 2024 qtr

Cipla gets USFDA nod for generic cancer drug

Business Line | 11 Apr 2025 1 more

Aurobindo Pharma Ltd.

11 Apr 2025

1171.60

3.37%

Aurobindo Pharma shares jump 4% as arm completes phase1 trial for bone drug

Business Standard

Denosumab works by specifically targeting the RANK ligand (RANKL), a critical protein in the lifecycle of osteoclasts, the cells that break down bone

Aurobindo Pharma Ltd. has an average target of 1501.00 from 10 brokers.

Abbott India Ltd.

11 Apr 2025

30690.00

-0.07%

[Initiation] Abbott India (BUY): A safe pick amidst tariff woes

Buy: Abbott India Ltd.

BOB Capital Markets Ltd.

Sales expected to reach USD 1bn, driven by industry-leading MR productivity of Rs 14.9mn by FY27E from Rs 11.5mn in FY24

Abbott India Ltd. has an average target of 32748.00 from 4 brokers.

Granules India Ltd.

10 Apr 2025

467.50

0.96%

Granules India completes acquisition of Swiss CDMO Senn Chemicals AG

Business Standard

The acquisition was executed through Granules' wholly owned subsidiary, Granules Peptides

Granules India Ltd. has lost -21.72% in the last 6 Months

Granules India completes acquisition of Senn Chemicals

Business Line | 10 Apr 2025

Sun Pharmaceutical Industries Ltd.

10 Apr 2025

1751.50

3.45%

US court clears Sun Pharma to launch Leqselvi for alopecia areata treatment

Business Standard

Sun Pharma is now preparing to launch the drug in US markets after facing legal issues since November 2024

Promoters pledged 0.19% of shares in last quarter. Total pledge stands at 0.88% of promoter holdings

Sun Pharmaceutical Industries Ltd.

10 Apr 2025

1751.50

3.45%

Sun Pharmasays US appeals court removes injunction on Leqselvilaunch

Business Line

The pharma stock closed 2 per cent lower on Wednesday. Trading operations will resume on April 11.

Sun Pharmaceutical Industries Ltd. is trading below its 150 day SMA of 1786.1

Sun Pharmaceutical Industries Ltd.

10 Apr 2025

1751.50

3.45%

Order vacating injunction on Leqselvi a material positive

Buy: Sun Pharmaceutical Industr...

Emkay

The US Court of Appeals has vacated the preliminary injunction against Sun Pharma’s launch of Leqselvi which was granted by the US District Court of New Jersey in Nov-24.